Gesine Bug
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gesine Bug has a total of 644 co-authors. Here are the top co-authors by number of shared publications:
- Mohamad Mohty
Department of Haematology, Saint Antoine Hospital, Paris, France
16 shared publications - Myriam Labopin
EBMT Paris Study Office, Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
14 shared publications - Ali Bazarbachi
Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
13 shared publications - Arnon Nagler
Division of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
13 shared publications - Fabio Ciceri
Ospedale San Raffaele, Haematology and BMT, Milano, Italy
13 shared publications - Matthias Stelljes
University of Muenster, Muenster, Germany
11 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Treatment of Severe Acute Graft-Versus-Host Disease Refractory to Multiple Lines of Therapy: Real-World Data from 317 Adults Treated with the Multiple-Donor Bone Marrow-Derived Mesenchymal Stromal Cell Preparation Tomostrocel
- 12 September 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Open AccessTreatment of Severe Acute Graft-Versus-Host Disease Refractory to Multiple Lines of Therapy: Real-World Data from 317 Adults Treated with the Multiple-Donor Bone Marrow-Derived Mesenchymal Stromal Cell Preparation Tomostrocel
- Open Access
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1783-1796
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
- 18 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1783-1796
Open AccessTreatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study
Summary: Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two randomized trials. We analysed its efficacy and safety in a real‐world cohort of r/r AML patients undergoing gilteritinib treatment including allogeneic haematopoietic stem cell transplantation (alloHSCT). Data were collected from all consecutive r/r AML patients with FLT3‐internal tandem duplication and/or FLT3‐tyrosine kinase domain mutations receiving gilteritinib at 25 centres. Response and survival were analysed using descriptive and correlative statistics. A total of 156 patients were analysed, 55.1% with relapse after previous alloHSCT, and 46.2% with prior FLT3 inhibitor exposure. The overall complete remission/incomplete remission (CR/Cri) rate was 45.3%, with a median overall survival (OS) of 10.0 months. Patients receiving gilteritinib only had a 1‐year OS of 34%, while those with consolidating alloHSCT had a 1‐year OS of 76%–92%, depending on gilteritinib maintenance post‐transplant. Resuming gilteritinib post‐transplant led to an 85.7% CR/CRi rate. Our real‐world data confirm that gilteritinib is an effective single‐agent therapy for r/r AML with FLT3 mutations, with best outcomes when used as a bridge to transplant and post‐transplant maintenance.
- Open Access
- 8 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1238-1245
Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT
There are very limited data on treosulfan (Treo)-based conditioning before allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute lymphoblastic leukemia. We aimed to compare fludarabine with Treo (FluTreo) or total body irradiation (FluTBI) in this setting. The final matched-pair analysis included ALL patients transplanted in complete remission after FluTreo (n = 153) or FluTBI (n = 431). The median patient age was 56.5 and 54.1 years, respectively. The allograft was derived from an unrelated (54.2% in FluTreo and 52% FluTBI group), matched sibling (30.7% and 32.5%) or haploidentical donor (15% and 15.5%). The incidence of acute graft-versus-host disease (GVHD) grade II-IV was 26.6% in the FluTreo and 30% in the FluTBI group (p = 0.43). The 2-year incidence of chronic GVHD was 33.5% and 40.7%, respectively (p = 0.23). The 2-year incidence of relapse and non-relapse mortality was 28.1% and 25.6% in the FluTreo and 25.1% and 20.4%, respectively, in the FluTBI group (p = 0.15 and p = 0.38). Leukemia-free survival and overall survival was 46.2% and 55% in the FluTreo and 54.5% and 61.3%, respectively, in the FluTBI group (p = 0.1 and p = 0.22). GVHD-free and relapse-free survival was 33.7% and 40.8%, respectively, in FluTreo and FluTBI patients (p = 0.06). In conclusion, there were no significant differences in transplant outcomes between the studied groups.
- 8 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1238-1245
Open AccessFludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT
There are very limited data on treosulfan (Treo)-based conditioning before allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute lymphoblastic leukemia. We aimed to compare fludarabine with Treo (FluTreo) or total body irradiation (FluTBI) in this setting. The final matched-pair analysis included ALL patients transplanted in complete remission after FluTreo (n = 153) or FluTBI (n = 431). The median patient age was 56.5 and 54.1 years, respectively. The allograft was derived from an unrelated (54.2% in FluTreo and 52% FluTBI group), matched sibling (30.7% and 32.5%) or haploidentical donor (15% and 15.5%). The incidence of acute graft-versus-host disease (GVHD) grade II-IV was 26.6% in the FluTreo and 30% in the FluTBI group (p = 0.43). The 2-year incidence of chronic GVHD was 33.5% and 40.7%, respectively (p = 0.23). The 2-year incidence of relapse and non-relapse mortality was 28.1% and 25.6% in the FluTreo and 25.1% and 20.4%, respectively, in the FluTBI group (p = 0.15 and p = 0.38). Leukemia-free survival and overall survival was 46.2% and 55% in the FluTreo and 54.5% and 61.3%, respectively, in the FluTBI group (p = 0.1 and p = 0.22). GVHD-free and relapse-free survival was 33.7% and 40.8%, respectively, in FluTreo and FluTBI patients (p = 0.06). In conclusion, there were no significant differences in transplant outcomes between the studied groups.
- Open Access
- 16 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1301.e1-1301.e10
Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome
- 16 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1301.e1-1301.e10
Open AccessAllogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome
- Open Access
- 15 June 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (8) , 1802-1806
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study
- 15 June 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (8) , 1802-1806
Open AccessAllogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study
- Open Access
- 10 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1323-1336
First-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia
PURPOSE: Patients with high-risk (HR) leukemia remain at substantial risk of early relapse, treatment-related toxicity, and poor survival, underscoring the need for effective relapse prevention therapies. To our knowledge, this first-in-human, disease burden–guided study evaluated the feasibility, safety, and efficacy of donor-derived allogeneic interleukin-15–activated cytokine-induced killer cells (IL15-CIK) combining T-cell and natural killer cell properties for post-transplant disease control. METHODS: In a prospective, multicenter phase I/II trial (EudraCT 2013-005446-11) and an identically designed pilot study, 53 adult and pediatric patients with HR leukemia received 56 courses of IL15-CIK monotherapy after human leukocyte antigen (HLA)–matched or HLA-mismatched transplantation. Treatment intent was categorized as consolidation (13%), preemptive (61%), or salvage (27%) with 169 infusions administered as a single dose (29%) or according to adaptable dose-escalation regimens (71%). RESULTS: Acute graft-versus-host disease (GVHD) grades 1-2 and grade 3 occurred in 27% and 4% of cases, respectively; no extensive chronic GVHD or treatment-related mortality was observed. IL15-CIK–associated adverse events were predominantly mild. Disease clearance, assessed by the cumulative incidence of complete molecular remission, peaked at day 700, reaching 74% in the preemptive and 13% in the salvage setting. The five-year progression-free survival was 50% overall and highest (69%) in pediatric acute myeloid leukemia. The five-year overall survival (OS) was 71% in the consolidation, 61% in the preemptive, and 20% in the salvage setting. Multivariable analysis demonstrated significantly lower relapse rates with Campath compared with ATG, superior OS in myeloid malignancies, and reduced IL15-CIK efficacy in advanced disease. The median follow-up was 7.3 years. CONCLUSION: IL15-CIK monotherapy is feasible and safe and demonstrates promising relapse-preventive activity after hematopoietic stem-cell transplantation. Clinical outcomes are strongly influenced by disease burden at treatment initiation and previous serotherapy, supporting optimized patient selection and timing in future post-transplant immunotherapeutic strategies.
- 10 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1323-1336
Open AccessFirst-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia
PURPOSE: Patients with high-risk (HR) leukemia remain at substantial risk of early relapse, treatment-related toxicity, and poor survival, underscoring the need for effective relapse prevention therapies. To our knowledge, this first-in-human, disease burden–guided study evaluated the feasibility, safety, and efficacy of donor-derived allogeneic interleukin-15–activated cytokine-induced killer cells (IL15-CIK) combining T-cell and natural killer cell properties for post-transplant disease control. METHODS: In a prospective, multicenter phase I/II trial (EudraCT 2013-005446-11) and an identically designed pilot study, 53 adult and pediatric patients with HR leukemia received 56 courses of IL15-CIK monotherapy after human leukocyte antigen (HLA)–matched or HLA-mismatched transplantation. Treatment intent was categorized as consolidation (13%), preemptive (61%), or salvage (27%) with 169 infusions administered as a single dose (29%) or according to adaptable dose-escalation regimens (71%). RESULTS: Acute graft-versus-host disease (GVHD) grades 1-2 and grade 3 occurred in 27% and 4% of cases, respectively; no extensive chronic GVHD or treatment-related mortality was observed. IL15-CIK–associated adverse events were predominantly mild. Disease clearance, assessed by the cumulative incidence of complete molecular remission, peaked at day 700, reaching 74% in the preemptive and 13% in the salvage setting. The five-year progression-free survival was 50% overall and highest (69%) in pediatric acute myeloid leukemia. The five-year overall survival (OS) was 71% in the consolidation, 61% in the preemptive, and 20% in the salvage setting. Multivariable analysis demonstrated significantly lower relapse rates with Campath compared with ATG, superior OS in myeloid malignancies, and reduced IL15-CIK efficacy in advanced disease. The median follow-up was 7.3 years. CONCLUSION: IL15-CIK monotherapy is feasible and safe and demonstrates promising relapse-preventive activity after hematopoietic stem-cell transplantation. Clinical outcomes are strongly influenced by disease burden at treatment initiation and previous serotherapy, supporting optimized patient selection and timing in future post-transplant immunotherapeutic strategies.
- 22 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (8) , 1806-1810
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a severe complication of CAR T-cell therapy affecting 20–65% of patients receiving anti-CD19 directed CAR T-cell therapy [1]. Neuro...
- 22 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (8) , 1806-1810
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a severe complication of CAR T-cell therapy affecting 20–65% of patients receiving anti-CD19 directed CAR T-cell therapy [1]. Neuro...
- Open Access
- 6 March 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (4) , 462-468
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
For patients with high-risk acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (HCT) remains standard of care. In the setting of an HLA-matched unrelated donor HCT, in vivo T-cell depletion (TCD) for prophylaxis of graft versus host disease (GVHD) relies on anti-thymocyte globulin (ATG) in Europe and alemtuzumab in the UK. In a retrospective study from the EBMT registry, we pair-matched 90 ALL patients aged ≥40 years transplanted in CR1 according to age (median 56 years) and ALL subtype (37.8% Ph-negative B-ALL, 46.7% Ph-positive B-ALL, 15.6% T-ALL). Reduced-intensity conditioning included fludarabine/melphalan (94.4%) in the alemtuzumab and fludarabine/busulfan (36.7%), fludarabine/total body irradiation (21.1%), fludarabine/melphalan (14.4%) and thiotepa/busulfan/fludarabine (13.3%) in the ATG group. Two-year leukemia-free and overall survival were similar between groups (Alemtuzumab: 56.4% vs ATG: 50.7%, HR 0.82, p = 0.34, and 62.7% vs 62.9%, HR 0.91, p = 0.67), as were cumulative incidence of relapse (23.7% vs 23.9%, HR 0.89, p = 0.69) and non-relapse mortality (19.9% vs 25.4%, HR 0.75, p = 0.32), resulting in similar GVHD- and relapse-free survival (GRFS) of 48.9% vs 42.1%, HR 0.8, p = 0.24. With GVHD and infections as main reasons for death in both groups, we conclude that both IS strategies are both safe for RIC HCT of these ALL patients.
- 6 March 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (4) , 462-468
Open AccessAnti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
For patients with high-risk acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (HCT) remains standard of care. In the setting of an HLA-matched unrelated donor HCT, in vivo T-cell depletion (TCD) for prophylaxis of graft versus host disease (GVHD) relies on anti-thymocyte globulin (ATG) in Europe and alemtuzumab in the UK. In a retrospective study from the EBMT registry, we pair-matched 90 ALL patients aged ≥40 years transplanted in CR1 according to age (median 56 years) and ALL subtype (37.8% Ph-negative B-ALL, 46.7% Ph-positive B-ALL, 15.6% T-ALL). Reduced-intensity conditioning included fludarabine/melphalan (94.4%) in the alemtuzumab and fludarabine/busulfan (36.7%), fludarabine/total body irradiation (21.1%), fludarabine/melphalan (14.4%) and thiotepa/busulfan/fludarabine (13.3%) in the ATG group. Two-year leukemia-free and overall survival were similar between groups (Alemtuzumab: 56.4% vs ATG: 50.7%, HR 0.82, p = 0.34, and 62.7% vs 62.9%, HR 0.91, p = 0.67), as were cumulative incidence of relapse (23.7% vs 23.9%, HR 0.89, p = 0.69) and non-relapse mortality (19.9% vs 25.4%, HR 0.75, p = 0.32), resulting in similar GVHD- and relapse-free survival (GRFS) of 48.9% vs 42.1%, HR 0.8, p = 0.24. With GVHD and infections as main reasons for death in both groups, we conclude that both IS strategies are both safe for RIC HCT of these ALL patients.
- Open Access
- 15 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (5) , 565-574
Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group
- 15 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (5) , 565-574
Open AccessPretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group
- Open Access
- 6 December 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (2) , 281-290
Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP / EBMT
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for secondary acute myeloid leukemia (sAML). This study compared haploidentical donor (Haplo), matched sibling donor (MSD), and matched unrelated donor (MUD) HSCT in patients with sAML in first complete remission (CR1). Data from 3862 patients (Haplo = 643, MSD = 715, MUD = 2504) transplanted between 2010 and 2022 were analyzed, with a median follow‐up of 3.3 years. Groups differed in patient and donor age, conditioning regimen, stem cell source, and graft‐versus‐host disease (GVHD) prophylaxis. Multivariate analysis showed that MSD‐HSCT had a higher relapse risk than Haplo‐HSCT (hazard ratio [HR]: 1.64) but lower non‐relapse mortality (NRM, HR: 0.32) and acute GVHD risk (HR: 0.54 for grade II–IV), leading to an overall survival (OS) benefit (HR: 0.76). MUD‐HSCT had lower NRM than Haplo‐HSCT (HR: 0.63) but there were no significant differences in OS or GVHD risk. Donor type did not impact leukemia‐free survival (LFS) or GVHD‐free and relapse‐free survival (GRFS). Adverse cytogenetics and reduced‐intensity conditioning were associated with increased relapse risk, while lower Karnofsky scores, older age, and adverse cytogenetics independently predicted worse NRM, LFS, OS, and GRFS outcomes. Female‐to‐male donor‐recipient pairs had an increased risk of chronic GVHD. In this registry‐based analysis, MSD offered the best outcomes for sAML in CR1. Haplo‐HSCT was comparable to MUD‐HSCT, despite a higher NRM, and achieved long‐term disease control in 60% of patients due to a low relapse incidence. In the absence of an MSD, both Haplo and MUD are viable alternatives.
- 6 December 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (2) , 281-290
Open AccessNon‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP / EBMT
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for secondary acute myeloid leukemia (sAML). This study compared haploidentical donor (Haplo), matched sibling donor (MSD), and matched unrelated donor (MUD) HSCT in patients with sAML in first complete remission (CR1). Data from 3862 patients (Haplo = 643, MSD = 715, MUD = 2504) transplanted between 2010 and 2022 were analyzed, with a median follow‐up of 3.3 years. Groups differed in patient and donor age, conditioning regimen, stem cell source, and graft‐versus‐host disease (GVHD) prophylaxis. Multivariate analysis showed that MSD‐HSCT had a higher relapse risk than Haplo‐HSCT (hazard ratio [HR]: 1.64) but lower non‐relapse mortality (NRM, HR: 0.32) and acute GVHD risk (HR: 0.54 for grade II–IV), leading to an overall survival (OS) benefit (HR: 0.76). MUD‐HSCT had lower NRM than Haplo‐HSCT (HR: 0.63) but there were no significant differences in OS or GVHD risk. Donor type did not impact leukemia‐free survival (LFS) or GVHD‐free and relapse‐free survival (GRFS). Adverse cytogenetics and reduced‐intensity conditioning were associated with increased relapse risk, while lower Karnofsky scores, older age, and adverse cytogenetics independently predicted worse NRM, LFS, OS, and GRFS outcomes. Female‐to‐male donor‐recipient pairs had an increased risk of chronic GVHD. In this registry‐based analysis, MSD offered the best outcomes for sAML in CR1. Haplo‐HSCT was comparable to MUD‐HSCT, despite a higher NRM, and achieved long‐term disease control in 60% of patients due to a low relapse incidence. In the absence of an MSD, both Haplo and MUD are viable alternatives.